Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Isuventatug · CLN-619

Monoclonal antibody · Immune activation, directed at MICA and MICB · developed by Cullinan Therapeutics

Phase 1 Most advanced trial
CGEM Developer
1 Registered trials

What is Isuventatug?

Isuventatug (CLN-619) is a human IgG1 monoclonal antibody that binds the alpha3 domain of the stress-induced NKG2D ligands MICA and MICB on tumor cells. It blocks their cleavage by tumor microenvironment proteases, preserving NKG2D engagement that activates NK cells and enables antibody-dependent cell-mediated cytotoxicity. It is being studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CLN-619
Drug type
Monoclonal antibody
Targets
MICA, MICB
Mechanism
Immune activation, directed at MICA and MICB
Pathways
NKG2D-mediated NK cell activation, antibody-dependent cell-mediated cytotoxicity
Therapy area
Oncology
Developer
Cullinan Therapeutics Inc. (CGEM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
MK3GM5GP7S

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06381141 Phase 1 Multiple Myeloma Active not recruiting CGEM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

More from Cullinan Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.

Follow CGEM, the company behind Isuventatug

See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.